StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note published on Friday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
ACRX has been the topic of several other research reports. HC Wainwright dropped their target price on AcelRx Pharmaceuticals from $8.00 to $5.00 and set a buy rating on the stock in a report on Monday, September 25th. Alliance Global Partners started coverage on AcelRx Pharmaceuticals in a report on Monday, October 2nd. They set a buy rating and a $4.25 price objective on the stock.
AcelRx Pharmaceuticals Trading Up 1.3 %
Institutional Investors Weigh In On AcelRx Pharmaceuticals
Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new position in shares of AcelRx Pharmaceuticals during the 1st quarter worth approximately $27,000. Virtu Financial LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the 2nd quarter valued at $29,000. Cowen AND Company LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the 3rd quarter valued at $67,000. Values First Advisors Inc. grew its stake in shares of AcelRx Pharmaceuticals by 201.7% during the 2nd quarter. Values First Advisors Inc. now owns 122,441 shares of the specialty pharmaceutical company’s stock valued at $136,000 after buying an additional 81,854 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of AcelRx Pharmaceuticals during the 4th quarter valued at $144,000. Institutional investors and hedge funds own 19.79% of the company’s stock.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain.
- Five stocks we like better than AcelRx Pharmaceuticals
- 3 Best Fintech Stocks for a Portfolio Boost
- The most upgraded stocks in November have two things in common
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Monday.com rocked earnings like it’s the weekend
- Basic Materials Stocks Investing
- Plan to own one retailer? Make it this one
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.